Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response
NCT03831230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250
Last updated 2025-08-08
Summary
Development of ex vivo models of ovarian cancer, fallopian tubes or peritoneum.
Conditions
Interventions
- GENETIC
-
collection of blood, urine, tumor and ascite samples
collection of blood, urine, tumor and ascite samples during ovarian surgery
Sponsors & Collaborators
-
Centre Francois Baclesse
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-07
- Primary Completion
- 2025-02-27
- Completion
- 2025-02-27
Countries
- France
Study Locations
More Related Trials
-
Prognostic and Predictive Biomarkers in Ovarian Cancers
NCT03010124 ·Status: RECRUITING ·Phase: NA
-
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122 ·Status: COMPLETED
-
Individualized Precision Treatment Based on Ovarian Cancer Organoid Model
NCT05813509 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
NCT04770376 ·Status: UNKNOWN
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900560 ·Status: TERMINATED ·Phase: PHASE2
-
Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
NCT02323568 ·Status: COMPLETED ·Phase: NA
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma
NCT03302884 ·Status: UNKNOWN ·Phase: NA
-
French Observatory of Rare Malignant Tumors of the Ovary
NCT01304043 ·Status: COMPLETED
-
Pharmacogenomics of Paclitaxel in Ovarian Cancer
NCT00415207 ·Status: COMPLETED
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN
-
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
NCT02591095 ·Status: COMPLETED ·Phase: PHASE2
-
Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer
NCT03881683 ·Status: COMPLETED ·Phase: NA
-
Genomic BRCA and Extensive ovArian Cancer Testing
NCT04027868 ·Status: COMPLETED
-
Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors
NCT01440504 ·Status: COMPLETED
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
NCT05204342 ·Status: COMPLETED
-
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961 ·Status: UNKNOWN
-
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers
NCT03976999 ·Status: RECRUITING ·Phase: NA
-
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
NCT05976932 ·Status: UNKNOWN
-
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NCT06969833 ·Status: RECRUITING ·Phase: NA
-
Oxford Ovarian Cancer Predict Chemotherapy Response 01
NCT01770535 ·Status: UNKNOWN
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
NCT02406235 ·Status: COMPLETED